Arbor Partners

Arbor Biotechnologies is a next-generation gene editing company developing a diverse portfolio of genetic medicines. Utilizing a proprietary discovery engine, the company identifies novel, programmable DNA editors, such as Cas12i2, to overcome the limitations of existing CRISPR technologies. Their lead clinical candidate, ABO-101, is an in vivo gene editing therapy targeting the HAO1 gene for the treatment of Primary Hyperoxaluria Type 1 (PH1). Beyond liver diseases, Arbor is advancing programs in the central nervous system, including therapies for amyotrophic lateral sclerosis (ALS), and maintains strategic collaborations with industry leaders like Chiesi Group and Acuitas Therapeutics.